Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

CHICAGO, June 5, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.  A total of 33 women in the study with prior Doxil® (pegylated liposomal doxorubicin or PLD) treatment were evaluable for response rate using either RECIST 1.0 criteria (response by tumor imaging) or Gynecologic Cancer InterGroup (GCIG) criteria, which is a combination of RECIST and/or ovarian cancer biomarker (CA-125) criteria.(1)  Confirmed and unconfirmed objective response rates using RECIST were 25 percent (4/16) and 29 percent (4/14) for the q14d and q21d dose schedules, respectively.  Confirmed objective response rates using RECIST were 19 percent (3/16) and 21 percent (3/14) for each dose schedule, respectively.  GCIG (confirmed and unconfirmed) response rates were 50 percent (8/16) in the once every 14 days (q14d) dose schedule and 35 percent (6/17) for the once every 21 days (q21d) dose schedule.  Confirmed objective GCIG response rates were 38 percent (6/16) and 35 percent (6/17) in the q14d and q21d dose schedules, respectively.

Median progression-free survival for all 33 patients in the subpopulation previously treated with PLD was 5.4 months and median overall survival was 13.9 months.  The median duration of confirmed response was 4.2 months in the q14d schedule and 4.4 months in the q21d schedule.

"NKTR-102 exhibits an exceptionally high response rate and long median survival compared to what would be expected in this group of heavily pre-treated women with platinum-resistant and refractory ovarian cancer," said Dr. Agustin Garcia, Associate Professor of Clinical Medicine at USC Norris Comprehensive Center.  "Women whose cancer has progressed following trea
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- China Nepstar Chain Drugstore Ltd. (NYSE: ... retail drugstore chain in China based on the ... unaudited financial results for the second quarter ended June ... ended June 30, 2014: , Revenue increased by ... million in the second quarter of 2013 ...
(Date:8/27/2014)... , Aug. 27, 2014 TWi Pharmaceuticals, ... approval from the United States Food and Drug ... (ANDA) for megestrol acetate 125mg/ml oral suspension, the ... is the first-to-file and under Hatch Waxman rules, ... marketing exclusivity.  TWi has completed the pre-launch preparation ...
(Date:8/27/2014)... , Aug. 27, 2014 ... report: Collaborative R&D Terms & ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The Collaborative ... and Diagnostics report provides comprehensive understanding and ... and agreements entered into by the worlds ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... Inc. (NYSE: SMA ), a leading independent provider ... other medical markets, announced today updated full year 2009 ... flow resulting from lower than anticipated customer demand for ... markets, Symmetry is adjusting its previously stated annual revenue ...
... 26 Ethicon Endo-Surgery today announced results from two ... in three common procedures resulted in a reduced rate ... a difference of more than $15,000 on average for ... study compared two types of minimally invasive hysterectomy procedures ...
Cached Medicine Technology:Symmetry Medical Updates Full Year 2009 Financial Guidance 2Symmetry Medical Updates Full Year 2009 Financial Guidance 3New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared to Open Surgery 2New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared to Open Surgery 3New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared to Open Surgery 4New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared to Open Surgery 5
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The need for ... over the past few years. The new location - 4700 ... higher quality and larger office space than TLC had in ... , “We are pleased about our new location because it ... our suite will be double in size compared to the ...
(Date:8/27/2014)... Author and orthopedic surgeon William H. Simon’s ... thrilling adventures of sharp and witty Dr. Ham ... up for a new marketing push in the second ... , “Prescription: Murder” follows the adventures of Ham Marks, ... attempts and thwarting criminals. In the first novella, “Over ...
(Date:8/27/2014)... an innovative company that provides many kinds of top quality ... are now offered on its website. In addition, the firm ... that place an order for its newly released items can ... , The company’s senior spokesman was excited to talk ... and old customers can buy cheap bamboo panels on our ...
(Date:8/27/2014)... National Resident Matching Program International (NRMPI) ... Education in Europe (AMEE) Conference being held at the ... September 3, 2014. As an exhibitor, NRMPI will ... share the benefits of its matching services, and discuss ... countries throughout the world. , “Exhibiting at ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:William H. Simon Launches New Marketing Campaign for Book 2Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2
... CRANSTON, R.I., Nov. 27 A new, ... manufacturers (OEMs) on choosing the,right electronics manufacturing ... available free to download at, http://www.federalelec.com/medicalpaper ., ... need for consistent quality and,conformance to product ...
... 27, 2007, 4:00 p.m. E.S.T. - Positron emission tomography ... need for more accurate staging of lung cancer and ... published online today in Journal of National Cancer Institute. ... Cancer Disease Site Group of Cancer Care Ontarios Program ...
... Nov. 27 A new study that shows young ... for men has leveled off offers,strong evidence that preventive ... war on cardiovascular disease, said Christopher T. Fey, the,chairman ... released study published in Journal of the American College ...
... therapies, experts say , , TUESDAY, Nov. 27 (HealthDay News) ... doctors predict which postmenopausal women are likely to sustain ... algorithm includes 11 different factors -- such as age ... of different ethnic backgrounds. , "Knowing the 5-year ...
... Risk Elevated in Male BRCA Mutation Carriers , Men with ... of breast cancer than the general population. , Male breast cancer ... the U.S., and it is most common in men with a ... who carry mutations in the BRCA2 gene have a greater risk ...
... R.I. [Brown University] Heavy smoking and drinking are ... human papillomavirus type 16 (HPV16), a common strain of ... for head and neck cancer, which affects about 500,000 ... however, shows that alcohol and tobacco use doesnt further ...
Cached Medicine News:Health News:White Paper Details How to Choose the Right EMS Provider for Medical Products Outsourcing 2Health News:PET imaging significantly enhances standard imaging in lung cancer staging 2Health News:US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care 2Health News:US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care 3Health News:Criteria Predict Women's 5-Year Risk for Fracture 2Health News:Other Highlights in the Nov. 27 JNCI 2Health News:Other Highlights in the Nov. 27 JNCI 3Health News:Other Highlights in the Nov. 27 JNCI 4Health News:Drinking and smoking don't boost HPV-related cancer risk 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: